Scientific Article
Personalised human albumin in patients with cirrhosis and ascites: design and rationale for the ALB-TRIAL – a randomised clinical biomarker validation trial
Human albumin is used in the treatment of complications of cirrhosis. However, the use of long-term human albumin administration is costly and resource demanding for both patients and healthcare systems. A precision medicine approach with biomarkers to predict human albumin treatment response, so-called predictive biomarkers, could make this a viable treatment option in patients with cirrhosis and ascites.
Torp, N., Israelsen, M., Coenraad, M., Papp, M., Shawcross, D., Korenjak, M., Angeli, P., Laleman, W., Juanola, A., Gines, P., Trebicka, J., Krag, A.; MICROB-PREDICT Consortium. Personalised human albumin in patients with cirrhosis and ascites: design and rationale for the ALB-TRIAL – a randomised clinical biomarker validation trial. BMJ Open. 2024 Feb 14;14(2). doi: 10.1136/bmjopen-2023-079309. PMID: 38355195; PMCID: PMC10868305.
